Patents by Inventor Juan Martinez-Barea
Juan Martinez-Barea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11898199Abstract: The present disclosure provides, among other things, methods of screening for colorectal cancer, methods of screening for advanced adenoma, methods of screening for the presence of either colorectal cancer or advanced adenoma (or both), and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer and/or advanced adenoma screening that includes analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer and/or advanced adenoma screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for colorectal cancer and/or advanced adenoma screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR.Type: GrantFiled: November 11, 2019Date of Patent: February 13, 2024Assignee: Universal Diagnostics, S.A.Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Marko Chersicola, Primo{hacek over (z)} Knap
-
Publication number: 20230183815Abstract: The present disclosure provides, among other things, methods for colorectal neoplasm detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for adenoma and/or early stage colorectal cancer detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for detection (e.g., screening) that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for screening that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR and/or using massively parallel sequencing (e.g.Type: ApplicationFiled: December 23, 2022Publication date: June 15, 2023Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Pol Sola de los Santos, Pol Canal Noguer, Marko Chersicola, Primoz Knap
-
Patent number: 11530453Abstract: The present disclosure provides, among other things, methods for colorectal cancer, breast cancer, lung cancer and/or pancreatic cancer detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for detection (e.g., screening) that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for screening that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR and/or using massively parallel sequencing (e.g., next-generation sequencing).Type: GrantFiled: September 21, 2020Date of Patent: December 20, 2022Assignee: Universal Diagnostics, S.L.Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Pol Sola de los Santos, Pol Canal Noguer, Marko Chersicola, Primoz̆ Knap
-
Publication number: 20220389521Abstract: The present disclosure provides, among other things, methods for colorectal cancer screening and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR.Type: ApplicationFiled: June 21, 2022Publication date: December 8, 2022Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Marko Chersicola, Primoz Knap
-
Patent number: 11396679Abstract: The present disclosure provides, among other things, methods for colorectal cancer screening and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR.Type: GrantFiled: May 31, 2019Date of Patent: July 26, 2022Assignee: Universal Diagnostics, S.L.Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Marko Chersicola, Primo{hacek over (z)} Knap
-
Publication number: 20210404011Abstract: The present disclosure provides, among other things, methods for colorectal cancer, breast cancer, lung cancer and/or pancreatic cancer detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for detection (e.g., screening) that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for screening that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR and/or using massively parallel sequencing (e.g., next-generation sequencing).Type: ApplicationFiled: September 21, 2020Publication date: December 30, 2021Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Pol Sola de los Santos, Pol Canal Noguer, Marko Chersicola, Primo{hacek over (z)} Knap
-
Publication number: 20210404010Abstract: The present disclosure provides, among other things, methods for colorectal neoplasm detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for adenoma and/or early stage colorectal cancer detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for detection (e.g., screening) that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for screening that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR and/or using massively parallel sequencing (e.g.Type: ApplicationFiled: September 21, 2020Publication date: December 30, 2021Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Pol Sola de los Santos, Pol Canal Noguer, Marko Chersicola, Primo{hacek over (z)} Knap
-
Publication number: 20210355542Abstract: Described herein are various systems, methods, and apparatus for identifying biomarkers for detection of a disease or condition such as advanced adenoma, colorectal cancer, or other cancers. In certain embodiments, the present invention relates to methods and/or systems for identifying one or more biomarkers related to methylation status in cell-free deoxyribonucleic acid (DNA) of a human subject and/or detecting (e.g., screening for) cancer based on one or more known biomarkers (e.g., the identified biomarkers).Type: ApplicationFiled: September 21, 2020Publication date: November 18, 2021Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Pol Sola de los Santos, Pol Canal Noguer, Marko Chersicola, Primo{hacek over (z)} Knap
-
Publication number: 20210332440Abstract: The present disclosure provides, among other things, methods for adenoma and/or early stage colorectal cancer detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for detection (e.g., screening) that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for screening that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR and/or using massively parallel sequencing (e.g., next-generation sequencing).Type: ApplicationFiled: September 21, 2020Publication date: October 28, 2021Inventors: Kristi Kruusmaa, Christian Hense, Marko Bitenc, Juan Martinez-Barea, Pol Sola de los Santos, Pol Canal Noguer, Marko Chersicola, Primo{hacek over (z)} Knap
-
Publication number: 20210277487Abstract: The present disclosure provides, among other things, methods for colorectal cancer screening and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR.Type: ApplicationFiled: May 25, 2021Publication date: September 9, 2021Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Marko Chersicola, Primo{hacek over (z)} Knap
-
Publication number: 20210230707Abstract: The present disclosure provides, among other things, methods for colorectal cancer detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer detection (e.g., screening) that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR.Type: ApplicationFiled: April 6, 2021Publication date: July 29, 2021Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Pol Sola de los Santos, Pol Canal Noguer, Marko Chersicola, Primoz Knap
-
Publication number: 20210139948Abstract: The present disclosure provides, among other things, methods of screening for colorectal cancer, methods of screening for advanced adenoma, methods of screening for the presence of either colorectal cancer or advanced adenoma (or both), and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer and/or advanced adenoma screening that includes analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer and/or advanced adenoma screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for colorectal cancer and/or advanced adenoma screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR.Type: ApplicationFiled: November 11, 2019Publication date: May 13, 2021Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Marko Chersicola, Primoz Knap
-
Patent number: 11001898Abstract: The present disclosure provides, among other things, methods for colorectal cancer detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer detection (e.g., screening) that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR.Type: GrantFiled: March 26, 2020Date of Patent: May 11, 2021Assignee: Universal Diagnostics, S.L.Inventors: Marko Bitene, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Pol Sola de los Santos, Pol Canal Noguer, Marko Chersicola, Primo{hacek over (z)} Knap
-
Publication number: 20200377954Abstract: The present disclosure provides, among other things, methods for colorectal cancer screening and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include screening methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR.Type: ApplicationFiled: May 31, 2019Publication date: December 3, 2020Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Marko Chersicola, Primo{hacek over (z)} Knap
-
Publication number: 20200377959Abstract: The present disclosure provides, among other things, methods for colorectal cancer detection (e.g., screening) and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include analysis of methylation status of one or more methylation biomarkers, and compositions related thereto. In various embodiments, the present disclosure provides methods for colorectal cancer detection (e.g., screening) that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA. In various embodiments, the present disclosure provides methods for colorectal cancer screening that include detecting (e.g., screening) methylation status of one or more methylation biomarkers in cfDNA, e.g., in ctDNA, using MSRE-qPCR.Type: ApplicationFiled: March 26, 2020Publication date: December 3, 2020Inventors: Marko Bitenc, Kristi Kruusmaa, Juan Martinez-Barea, Christian Hense, Pol Sola de los Santos, Pol Canal Noguer, Marko Chersicola, Primo{hacek over (z)} Knap
-
Patent number: 10823744Abstract: Described herein are sets of metabolite and lipid (e.g., fatty acid) markers that can be used in the detection of early stage colorectal cancer and/or early development of adenomatous polyps. Presented herein are illustrative pathology-linked panels. In certain embodiments, the markers presented herein (or subsets thereof) are used as a panel for detecting either colorectal cancer or adenomatous polyps at the same time. The markers presented herein include metabolites and lipids (e.g., fatty acid) freely detectable and accurately quantifiable in human serum. In certain embodiments, the sample may be plasma, urine, saliva, whole blood, dried blood spot or dried serum spot.Type: GrantFiled: October 4, 2017Date of Patent: November 3, 2020Assignee: Universal Diagnostics, S.L.Inventors: Marko Bitenc, Kristi Kruusmaa, Paola Hurtado Castillo, Ana María Jiménez Girón, Rosa Argamasilla Martinez, Andreu Fabregat Rossell, Antonio Jesus Adsuar Gomez, Juan Martinez-Barea, Christian Hense, Patricia Rodríguez Gómez, Ángela Peralbo Molina, Jorge Casado Agrelo, Alejandro Sánchez Brotons, Cristina Pavón Solís, Rosa María Delgado Sánchez
-
Publication number: 20180196074Abstract: Described herein are sets of metabolite and lipid (e.g., fatty acid) markers that can be used in the detection of early stage colorectal cancer and/or early development of adenomatous polyps. Presented herein are illustrative pathology-linked panels. In certain embodiments, the markers presented herein (or subsets thereof) are used as a panel for detecting either colorectal cancer or adenomatous polyps at the same time. The markers presented herein include metabolites and lipids (e.g., fatty acid) freely detectable and accurately quantifiable in human serum. In certain embodiments, the sample may be plasma, urine, saliva, whole blood, dried blood spot or dried serum spot.Type: ApplicationFiled: October 4, 2017Publication date: July 12, 2018Inventors: Marko Bitenc, Kristi Kruusmaa, Paola Hurtado Castillo, Ana María Jiménez Girón, Rosa Argamasilla Martinez, Andreu Fabregat Rossell, Antonio Jesus Adsuar Gomez, Juan Martinez-Barea, Christian Hense, Patricia Rodríguez Gómez, Ángela Peralbo Molina, Jorge Casado Agrelo, Alejandro Sánchez Brotons, Cristina Pavón Solís, Rosa María Delgado Sánchez
-
Patent number: 10006925Abstract: Described herein are sets of metabolite and lipid (e.g., fatty acid) markers that can be used in the detection of early stage colorectal cancer and/or early development of adenomatous polyps. Presented herein are illustrative pathology-linked panels. In certain embodiments, the markers presented herein (or subsets thereof) are used as a panel for detecting either colorectal cancer or adenomatous polyps at the same time. The markers presented herein include metabolites and lipids (e.g., fatty acid) freely detectable and accurately quantifiable in human serum. In certain embodiments, the sample may be plasma, urine, saliva, whole blood, dried blood spot or dried serum spot.Type: GrantFiled: March 14, 2017Date of Patent: June 26, 2018Assignee: Universal Diagnostics, S. L.Inventors: Marko Bitenc, Kristi Kruusmaa, Paola Hurtado Castillo, Ana María Jiménez Girón, Rosa Argamasilla Martinez, Andreu Fabregat Rossell, Antonio Jesus Adsuar Gomez, Juan Martinez-Barea, Christian Hense, Patricia Rodríguez Gómez, Ángela Peralbo Molina, Jorge Casado Agrelo, Alejandro Sánchez Brotons, Cristina Pavón Solís, Rosa María Delgado Sánchez
-
Patent number: 10001501Abstract: Described herein are automated and customizable sample preparation and analysis systems for detection and quantification of biomarkers (e.g., metabolites and/or lipids) in biological samples (e.g., blood, serum, or plasma) in a clinical setting. The automated systems are controlled by scripts that integrate communication between the components of the sample preparation system. Also described herein are mass spectrometry-based analytical methods featuring efficient system calibration and sample analysis that provide for accurate quantification of a set of markers in biological samples. The methods are capable of automatic high sample throughput in a clinical setting for detection and quantification using a mass spectrometry system and high performance liquid chromatography column.Type: GrantFiled: December 30, 2016Date of Patent: June 19, 2018Assignee: Universal Diagnostics, S. L.Inventors: Marko Bitenc, Kristi Kruusmaa, Paola Hurtado Castillo, Ana María Jiménez Girón, Rosa Argamasilla Martinez, Andreu Fabregat Rossell, Antonio Jesus Adsuar Gomez, Juan Martinez-Barea, Christian Hense, Patricia Rodríguez Gómez
-
Publication number: 20170343567Abstract: Described herein are sets of metabolite and lipid (e.g., fatty acid) markers that can be used in the detection of early stage colorectal cancer and/or early development of adenomatous polyps. Presented herein are illustrative pathology-linked panels. In certain embodiments, the markers presented herein (or subsets thereof) are used as a panel for detecting either colorectal cancer or adenomatous polyps at the same time. The markers presented herein include metabolites and lipids (e.g., fatty acid) freely detectable and accurately quantifiable in human serum. In certain embodiments, the sample may be plasma, urine, saliva, whole blood, dried blood spot or dried serum spot.Type: ApplicationFiled: March 14, 2017Publication date: November 30, 2017Inventors: Marko Bitenc, Kristi Kruusmaa, Paola Hurtado Castillo, Ana María Jiménez Girón, Rosa Argamasilla Martinez, Andreu Fabregat Rossell, Antonio Jesus Adsuar Gomez, Juan Martinez-Barea, Christian Hense, Patricia Rodríguez Gómez, Ángela Peralbo Molina, Jorge Casado Agrelo, Alejandro Sánchez Brotons, Cristina Pavón Solís, Rosa María Delgado Sánchez